Meningococcal vaccine adverse events reported to VAERS — reviewing post-market safety data for Menactra, Menveo, and related MenACWY conjugate vaccines.
Post-licensure findings on the meningococcal conjugate vaccines on the US schedule. The most significant finding is the CDC's own admission that MenACWY vaccines "probably" do not prevent transmission of meningococcal disease — a public health acknowledgment that directly undermines the herd immunity rationale used to justify mandatory adolescent vaccination. The source contains relatively limited MenACWY-specific post-licensure surveillance data beyond the system-level critiques applied to all vaccines on the schedule.
CDC: "Probably" Does Not Prevent Transmission
The CDC acknowledges that MenACWY vaccines "probably" do not prevent transmission of meningococcal disease. They protect vaccinated individuals from invasive disease but do not reliably block asymptomatic carriage and transmission of Neisseria meningitidis.
The exact CDC framing uses "probably" rather than a definitive yes or no — reflecting the CDC's acknowledgment that the evidence does not support a transmission-blocking claim while leaving open the possibility of partial reduction.
This admission has significant implications:
The herd immunity rationale for mandatory MenACWY vaccination of adolescents (the primary target population) is undermined
College and university MenACWY mandates rest on the assumption that vaccinating one student protects others — an assumption the CDC's own language does not support
The benefit calculation must be reframed as individual protection only, not population-level transmission reduction
See Herd Immunity for the broader pattern across multiple childhood vaccines.
CDC Autism Lawsuit Coverage
MenACWY is administered to adolescents (typically 11-12 years old, with a booster at 16), not to infants in the relevant developmental window for autism. The CDC autism lawsuit framework therefore applies less directly to MenACWY than to infant vaccines.
However, the broader pattern of inadequate post-licensure safety study applies. The CDC's stipulated 20 studies in the autism lawsuit did not include any examining MenACWY-specific outcomes. See Post-Licensure Safety Monitoring.
VAERS, VSD, V-SAFE Coverage
MenACWY vaccines are nominally subject to post-licensure surveillance through:
VAERS — passive reporting; estimated to capture <1% of actual adverse events
These surveillance systems have not generated regulatory action specific to MenACWY vaccines. See the linked concept pages for documentation of why these systems have not produced reliable post-licensure safety signals.
AHRQ Comprehensive Review
The 2014 AHRQ comprehensive review of 20,478 studies found zero qualifying safety studies for most routine childhood vaccines. The MenACWY vaccines are part of this finding. See Post-Licensure Safety Monitoring.
Does the meningococcal vaccine prevent transmission of meningococcal disease?
The CDC acknowledges that MenACWY vaccines "probably" do not prevent transmission of meningococcal disease. They protect vaccinated individuals from invasive disease but do not reliably block asymptomatic carriage and transmission of Neisseria meningitidis. This undermines college and university MenACWY mandates, which rest on the assumption that vaccinating one student protects others.
Are there comprehensive safety studies on meningococcal vaccines?
No. The 2014 AHRQ review examined 20,478 studies and found zero qualifying safety studies for most routine childhood vaccines, including MenACWY vaccines. Post-licensure surveillance through VAERS (captures less than 1% of events), VSD (moved to a trade association to evade FOIA), and V-SAFE (primarily for COVID-19) has not generated any regulatory action specific to MenACWY vaccines.
Has the CDC studied whether meningococcal vaccines cause autism?
MenACWY is given to adolescents (typically 11-12 years old), not during the infant developmental window relevant to autism. The CDC's stipulated 20 studies in the autism lawsuit did not include any examining MenACWY-specific outcomes. The broader pattern of inadequate post-licensure safety study documented across the schedule applies equally to MenACWY vaccines.
Why do colleges require the meningococcal vaccine?
College MenACWY mandates are based on the assumption that vaccination prevents transmission in communal living environments. However, the CDC's own acknowledgment that MenACWY "probably" does not prevent transmission undermines this rationale. The benefit must be reframed as individual protection only, not population-level transmission reduction. Meningococcal disease itself is rare, affecting a small number of adolescents and young adults annually.
What is the circular licensing problem with meningococcal vaccines?
The same clinical trial was used to certify the safety of both Menomune (as the control) and Menactra (as the test vaccine). Menomune's own package insert references the Menactra trial as evidence of its own safety. This circular licensing means neither product has an independent safety validation. Every subsequent MenACWY vaccine traces back through this unvalidated foundation.
This is the plain-HTML rendering of vaccines/post-licensure/MenACWY Vaccines.md, served for search
engines, AI crawlers, and accessibility tools. The interactive 3D version
of this wiki lives at vaccine-safety.org.